AC-D-NAL(2)-D-PCL-D-PAL-SER-N-ME-TYR-D-HOMOCIT-NLE-ARG-PRO-D-ALA-NH2

Name: AC-D-NAL(2)-D-PCL-D-PAL-SER-N-ME-TYR-D-HOMOCIT-NLE-ARG-PRO-D-ALA-NH2 in Prostate Cancer
Creator: Floatz
License: https://terminal.floatz.ai/terms

Prostate Cancer

Spectrum Pharmaceuticals, Incprotein_peptidePhase 2Dormant

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 59/ 100

Competitive context

514 Active assets in the Prostate Cancer cohort.

Asset / Sponsor	Phase	Rating
Avodart Bay State Clinical Trials, Inc.	Phase 4	BBB
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
Degarelix Bayer	Phase 4	BBB
PROPOFOL Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
AVOLVE Masonic Cancer Center, University of Minnesota	Phase 4	BB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →